|
Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
ISSN: 1596-5996 EISSN: 1596-5996
Vol. 15, No. 1, 2016, pp. 201-211
|
Bioline Code: pr16028
Full paper language: English
Document type: Review Article
Document available free of charge
|
|
Tropical Journal of Pharmaceutical Research, Vol. 15, No. 1, 2016, pp. 201-211
en |
Nanoformulations and Clinical Trial Candidates as Probably Effective and Safe Therapy for Tuberculosis
Laghari, Madeeha; Darwis, Yusrida; Memon, Abdul Hakeem; Khan, Arshad Ali; Abdulbaqi, Ibrahim Mohammed Tayeb & Assi, Reem Abou
Abstract
Tuberculosis (TB) is the main infectious disease causing 1.8 million deaths worldwide every year and
represents a principal cause of mortality resulting from a bacterial infection. The emergence of
multidrug-resistant strains and lack of effective anti-TB drugs are threatening the future control of TB.
The present multidrug regimen against TB needs daily administration for at least 6 months, and patients
often fail to follow this complex regimen for such a long interval, thus leading to patient non-compliance
and treatment related side effects. To avoid daily dosing, application of nanotechnology is a promising
solution by virtue of sustained drug release. Nanotechnology-based rational targeting may improve
therapeutic success by limiting adverse drug effects and requiring less frequent administration
regimens, ultimately resulting in higher patient compliance, and thus attain higher adherence levels.
Today, the pipeline of potential new treatments consists of several compounds in clinical trials or
preclinical development with promising activities against sensitive and resistant Mycobacterium
tuberculosis strains. Encapsulation of existing anti-TB drugs into nano-delivery systems and introduction
of new drugs in combination treatment for all forms of tuberculosis have resulted in novel treatments
with more effectiveness and reduced side effects.
Keywords
Tuberculosis; Nanotechnology; Anti-tuberculosis drugs; Nano carriers; Rifampicin
|
|
© Copyright 2016 - Tropical Journal of Pharmaceutical Research Alternative site location: http://www.tjpr.org
|
|